Sector: Pharmaceuticals & Biotechnology - Healthcare
BSE Code: 532989
NSE Symbol: BAFNAPH
ISIN: INE878I01022
📈 Bafna Pharmaceuticals Clarifies Recent Share Price Movement • Issued clarification letter to BSE and NSE on April 15, 2026 • Responded to specific exchange references (NSE: NSE/CM/Surveillance/16817, BSE: L/SURV/ONL/PV/APJ/2026-2027/3719) • Attributed share price movement to market-driven facto…
📊 Bafna Pharmaceuticals Appoints New Auditors for FY 2026-2027 • Appointed K. S. Rao & Co. as Internal Auditor for FY 2026-2027 (April 1, 2026 - March 31, 2027) • K. S. Rao & Co. is a Chartered Accountant firm with over 40 years of experience • Appointed N. Sivashankaran & Co. as Cost Auditor for…
📈 Bafna Pharmaceuticals Clarifies Share Price Movement - Clarification issued on March 24, 2026 regarding significant share price movement. - Company stated it is not aware of any specific information or event explaining the price change. - Attributed movement to market-driven factors, general ma…
📅 Bafna Pharmaceuticals Q3 FY2026 Results Board Meeting Scheduled • Board meeting scheduled for February 11, 2026 to consider and approve un-audited financial results for Q3 ended December 31, 2025. • Trading window closed for designated persons and their immediate relatives from January 1, 2026 …
📈 Bafna Pharma’s Credit Outlook Upgraded to ‘Positive’ by ICRA - ICRA revises Bafna Pharmaceuticals’ credit outlook from ‘Stable’ to ‘Positive’. - Total bank loan facilities rated: ₹50.00 Crores. - Long-term rating reaffirmed at [ICRA] BB+ (outlook now ‘Positive’). - Short-term rating remains unc…
📈 Bafna Pharmaceuticals Reports Growth: Key Financial Highlights for Q2 & H1 2025 - Property, Plant & Equipment rose to ₹6,500.09 lakhs (Sep 2025) from ₹5,877.99 lakhs (Mar 2025), signaling capacity expansion. - Total assets grew to ₹16,068.27 lakhs (Sep 2025) vs. ₹15,307.91 lakhs (Mar 2025). - Q…
Bafna Pharma Strengthens Board with Key Appointments & Reappointments 📅 - Mr. Navin Kumar appointed as Non-Executive, Independent Director for 1 year (effective June 23, 2025). Chartered Accountant with 13+ years in corporate finance, taxation, and compliance. - Mr. Palamadai Krishnan Sundaresan …
📅 Bafna Pharma Q1 Results: Board Meeting Set for Aug 12 - Board meeting scheduled for August 12, 2025 to approve Un-Audited Financial Results for Q1 ended June 30, 2025. - Trading Window closed from July 01, 2025 to August 14, 2025 for Designated Persons and their immediate relatives.
🏭 Bafna Pharmaceuticals Sells Chennai Manufacturing Unit to Navron Pharma - Sale of manufacturing unit at No. 13, S.V. Koil Street, Madhavaram, Chennai - 600060 to Navron Pharma Private Limited. - Agreement executed on June 23, 2025; transaction completed on June 30, 2025. - Total consideration r…
📊 Bafna Pharmaceuticals Announces Board Committee Changes Following Director Retirement • Mr. Palamadai Krishnan Sundaresan (DIN: 06954189) retires as Independent Director effective June 24, 2025. • He steps down as Chairman of the Audit Committee and Member of the Nomination & Remuneration Commi…
Bafna Pharmaceuticals Appoints Mr. Navin Kumar as Independent Director 📊 - Mr. Navin Kumar appointed as Additional Director (Non-Executive & Independent Director), effective June 23, 2025, for a term of one year. - He is a qualified Chartered Accountant with over 13 years of experience in corpora…
📊 Bafna Pharma Q3 2024: Revenue at ₹3,318.76 Lakhs, Returns to Profit • Q3 2024 revenue from operations: ₹3,318.76 lakhs • Nine-month revenue: ₹10,679.70 lakhs • Q3 2024 profit before tax: ₹94.77 lakhs (vs. loss of ₹294.24 lakhs in Q3 2023) • Nine-month profit before tax: ₹284.18 lakhs • Q3 2024 …